Welcome to our dedicated page for Cyclacel Phar Pr news (Ticker: CYCCP), a resource for investors and traders seeking the latest updates and insights on Cyclacel Phar Pr stock.
Cyclacel Pharmaceuticals reported clinical-stage oncology and capital-markets developments tied to CYCCP before later filings identified the issuer as Bio Green Med Solution. News about the company centered on plogosertib, a PLK1 inhibitor evaluated in solid tumors and hematological malignancies, with updates referencing cell cycle, epigenetics, transcriptional regulation and mitosis biology.
Recurring company news also covered preclinical publications involving biliary tract cancer and fibrolamellar hepatocellular carcinoma, financial results and cash runway commentary, private placements of convertible preferred stock and warrants, reverse stock-split actions, Nasdaq listing compliance matters, and changes affecting research and development tax credits following the liquidation of the U.K. subsidiary.
Cyclacel Pharmaceuticals, Inc. will release its first quarter 2024 financial results on May 14, 2024. The company focuses on developing innovative cancer treatments and will host a conference call and webcast to discuss the results.
Cyclacel Pharmaceuticals, a biopharmaceutical company, closed an $8.0 million private placement under NASDAQ rules, offering shares of common stock, series A warrants, and short-term series B warrants. The gross proceeds were $8.0 million, with H.C. Wainwright & Co. as the exclusive placement agent. The company plans to use the net proceeds for working capital and general corporate purposes.
Cyclacel Pharmaceuticals, Inc. announced an $8.0 million private placement under Nasdaq rules, offering shares of common stock and warrants to purchase more shares at a fixed price. The placement is expected to close on May 2, 2024, with H.C. Wainwright & Co. acting as the exclusive placement agent. The company plans to use the net proceeds for working capital and general corporate purposes.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.